Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International's Other Accumulated Expenses history spans 5 years, with the latest figure at $22.1 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 29.85% year-over-year to $22.1 million; the TTM value through Dec 2025 reached $22.1 million, up 29.85%, while the annual FY2025 figure was $22.1 million, 29.85% up from the prior year.
  • Other Accumulated Expenses reached $22.1 million in Q4 2025 per KNSA's latest filing, up from $628000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $25.0 million in Q4 2021 to a low of $111000.0 in Q2 2024.
  • Average Other Accumulated Expenses over 5 years is $8.5 million, with a median of $8.0 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 99.47% in 2022, then surged 15167.57% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $25.0 million in 2021, then crashed by 99.47% to $133000.0 in 2022, then skyrocketed by 6060.15% to $8.2 million in 2023, then surged by 108.06% to $17.0 million in 2024, then grew by 29.85% to $22.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Accumulated Expenses are $22.1 million (Q4 2025), $628000.0 (Q3 2025), and $16.9 million (Q2 2025).